In line with the checkpoint function of innate immunity, binding of CPG-oligodeoxynucleotides to host antigen-presenting cells accelerated GvHD in a recent murine study [45], whereas murine TLR9−/− recipients were protected from GvHD [46]. The gene discussed is TLR9; the disease is graft versus host disease.